Stability Protocols by Dosage Form

While the ICH Q1A(R2) storage conditions apply broadly across dosage form categories, the specific stability-indicating parameters monitored, and the...

While the ICH Q1A(R2) storage conditions apply broadly across dosage form categories, the specific stability-indicating parameters monitored, and the packaging configurations tested, are tailored to the physical and chemical characteristics of each dosage form. For solid oral dosage forms such as tablets and capsules, the stability protocol typically monitors assay, degradation products, dissolution performance, moisture content, and, where relevant, microbial limits, with samples stored in the primary packaging configuration intended for commercial distribution, since the moisture and gas barrier properties of blister packaging or bottle-closure systems directly influence the observed stability outcome.

Liquid and semi-solid dosage forms present additional stability considerations beyond those relevant to solids, owing to the greater molecular mobility and higher water activity characteristic of these systems, which generally accelerates hydrolytic degradation pathways. Stability protocols for liquids and semi-solids therefore place particular emphasis on pH drift over time, preservative content and continued antimicrobial efficacy, viscosity change, and, for suspensions and emulsions, physical stability parameters such as sedimentation, caking, or phase separation, in addition to the chemical assay and degradation product monitoring applied to all dosage forms.

Parenteral products require the most extensive stability protocol of all dosage form categories, incorporating not only chemical assay and degradation product testing but also sterility confirmation, endotoxin testing, particulate matter assessment, and, critically, container closure integrity testing throughout the proposed shelf-life, since any compromise of container closure integrity during storage would place the sterility of the product at risk. Novel drug delivery systems such as nanoparticles and liposomes require yet further protocol customisation, incorporating the colloidal stability parameters discussed in the previous chapter — particle size, polydispersity index, and zeta potential — alongside conventional chemical stability testing, reflecting the additional physical instability mechanisms, such as aggregation and Ostwald ripening, to which these systems are uniquely susceptible.

Across all dosage form categories, the selection of stability-indicating analytical methods is itself a matter of rigorous scientific and regulatory scrutiny: a stability-indicating method must be capable of accurately quantifying the intact drug substance in the presence of its degradation products, excipients, and any other formulation components, without interference, and the validation of such methods — commonly through forced degradation studies employing acid, base, oxidative, thermal, and photolytic stress — is itself an essential preparatory activity that precedes the initiation of any formal stability study.